Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE3

Conditions

Oral Squamous Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking university Shenzhen hospital, Shenzhen, Guangdong, China
Contact: Study coordinator (Hong-Yu Yang, M.D.) · hyyang192@hotmail.com · 0755-83923333
Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China
Contact: Study coordinator (Gang Chen, M.D.) · geraldchan@whu.edu.cn · +86 02787686215
Xiangya Hospital of Central South University, Changsha, Hunan, China
Contact: Study coordinator (Tong Su, M.D.) · sutong@csu.edu.cn · 0731-89753046

Study leads

Gang Chen, M.D.
Principal Investigator
Hospital of Stomatology, Wuhan University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma

Locally Advanced Oral Squamous Cell Carcinoma · Oral Squamous Cell Carcinoma (OSCC)

Abroad (travel likely)RecruitingPHASE3

Guangzhou, China

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Oral Squamous Cell Carcinoma · Neoadjvant Therapy · Anti-PD-1

Abroad (travel likely)RecruitingPHASE2, PHASE3

Shanghai, China

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Diffuse Astrocytoma, IDH-Mutant · Glioblastoma, IDH-wildtype · Brain Metastases, Adult

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beverly Hills, United States · Glendale, United States

Spectroscopic Analysis of Tongue Tumor Samples.

Mass Spectroscopy · Molecular Profile · Surgical Margins

Abroad (travel likely)Recruiting

Amiens, France